A5084015325- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer-related gene regulation
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- DNA and Nucleic Acid Chemistry
- Electrochemical sensors and biosensors
- Hippo pathway signaling and YAP/TAZ
- Maritime Navigation and Safety
- Protein Structure and Dynamics
- Acute Myocardial Infarction Research
- Transportation Planning and Optimization
- Cutaneous Melanoma Detection and Management
- Enzyme Structure and Function
- bioluminescence and chemiluminescence research
- Natural Products and Biological Research
- CRISPR and Genetic Engineering
- Innovation and Socioeconomic Development
- Viral gastroenteritis research and epidemiology
- Melanoma and MAPK Pathways
- RNA Research and Splicing
- Evacuation and Crowd Dynamics
- Photoreceptor and optogenetics research
- BRCA gene mutations in cancer
- RNA and protein synthesis mechanisms
Sidney Kimmel Cancer Center
2024
University of Pennsylvania
2020-2023
Thomas Jefferson University Hospital
2023
BGI Group (China)
2023
Thomas Jefferson University
2022
Franklin & Marshall College
2018-2019
University of Alabama at Birmingham
1996
Abstract Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma. (R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits multiple α-ketoglutarate–dependent enzymes, altering epigenetics and metabolism. Here, developing mIDH1-driven genetically engineered mouse models, we show that supports cholangiocarcinoma tumor maintenance through an immunoevasion program centered on dual (R)-2-hydroxyglutarate–mediated mechanisms: suppression of CD8+ T-cell activity...
Abstract The spatial and temporal atlas of gene expression in the human embryo at early gestation is critical understanding development, organogenesis, disease origins. We obtained spatiotemporal transcriptome from 90 sagittal sections 16 whole embryos 3 to 8 post-conception weeks by Stereo-seq with high resolution ultra-large field, establishing development trajectory/regulatory profiling 49 organs. uncovered organ-specific regulons as potential lineage-determining factors identified new...
e23234 Background: Many integrative oncology (IO) outpatient (OP) cancer care approaches—yoga, acupuncture, massage, physical activity—have demonstrated benefit and are now part of guideline care. We report on a pilot inpatient (IP) IO consultative service aimed at introducing patients families to time when cancer- treatment-related symptoms can be significant. As measure patient-centered care, we assessed patient’s change in perceived understanding, intention promote health, confidence plan...
e23231 Background: Integrative oncology (IO) is an evidence-informed field of cancer care the utilizes mind-body practices, natural products, lifestyle medicine from different traditions alongside conventional therapies. Many these components have growing evidence benefit and are part guideline recommendations. The Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University has integrative program that sought to identify patients’ understanding health, assess their utilization...
Supplementary Figure from Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
The active sites of subtilisin and trypsin have been studied by paired IR spectroscopic X-ray crystallographic studies. site serines the proteases were reacted with 4-cyanobenzenesulfonyl fluoride (CBSF), an inhibitor that contains a nitrile vibrational reporter. stretch vibration water-soluble model, potassium 4-cyanobenzenesulfonate (KCBSO), calibrated solvent studies in H2O/DMSO frequency-temperature line-slope (FTLS) method H2O THF. complexes examined FTLS slopes best fit lines for...
<div>Abstract<p>Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma. (R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits multiple α-ketoglutarate–dependent enzymes, altering epigenetics and metabolism. Here, developing mIDH1-driven genetically engineered mouse models, we show that supports cholangiocarcinoma tumor maintenance through an immunoevasion program centered on dual (R)-2-hydroxyglutarate–mediated mechanisms: suppression of...
<div>Abstract<p>Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma. (R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits multiple α-ketoglutarate–dependent enzymes, altering epigenetics and metabolism. Here, developing mIDH1-driven genetically engineered mouse models, we show that supports cholangiocarcinoma tumor maintenance through an immunoevasion program centered on dual (R)-2-hydroxyglutarate–mediated mechanisms: suppression of...
Supplementary Figure from Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
Although drug-eluting stents (DESs) have significantly reduced restenosis after percutaneous coronary intervention (PCI), repeat target vessel revascularization (TVR) treatment with new-generation DES is approximately 10% at 2 years.1Silber S. Windecker Vranckx P. Serruys RESOLUTE All Comers Investigators. Unrestricted randomized use of two new generation stents: 2-year patient-related versus stent-related outcomes from the trial.Lancet. 2011; 377: 1241-1247Abstract Full Text PDF PubMed...